The Biomarkers Consortium’s Cancer, Inflammation and Immunity, Metabolic Disorders and Neuroscience Steering Committees are responsible for identifying and moving forward promising pre-competitive biomarkers projects for implementation by the Biomarkers Consortium, as well as overseeing each individual project under its purview. The members of each Steering Committee represent a variety of sectors, including academia, government, industry and not-for-profit/advocacy organizations, and are led by two co-chairs representing two of the following three sectors: academia, government or industry.
| Linda Brady, Ph.D., NIH/NIMH (Co-Chair)
Penny Dacks, Ph.D., Association for Frontotemporal Degeneration (Co-Chair) Danielle Graham, Ph.D., Biogen (Co-Chair) William Potter, M.D., Ph.D., (Co-Chair Emeritus) Marc Aafjes, M.B.A., Deliberate AI Alexandre Akoulitchev, Ph.D., Oxford Biodynamics Anthony Bannon, Ph.D., AbbVie Daniel Barboriak, M.D., Radiological Society of North America Wade Berrettini, M.D., Ph.D., UPenn Kevin Bittman, Ph.D., Sengenics Mathias Blom, M.D., Ph.D., Rhino Health Diane Bovenkamp, Ph.D., BrightFocus Foundation Mark Brody, Ph.D., Evolution Research Group Jonathon Brzezinski, Ph.D., Clarivate Xuemei Cai, M.D., Pfizer Marc Cantillon, M.D., Sunbird Bio Maria Carrillo, Ph.D., Alzheimer’s Association® Leuan Clay, Ph.D., VivoSense Diana Davis, Ph.D., Danaher Diagnostics Theresa Ann Day , M.S., Eli Lilly Francesca DeSimone, Ph.D., Fujirebio US John Dwyer, J.D., Global Alzheimer’s Platform Foundation Lorna Farrelly, Ph.D., Regeneron Yuehan Feng, Ph.D., Biognosys AG Thomas Finn, Ph.D., FDA/CBER Bernard Fischer, M.D., FDA/CDER Mariana Fontes, Ph.D., Olink Proteomics Gopi Ganji, Ph.D., GSK Tim Hammond, Ph.D., Sanofi Glenn A. Harris, Ph.D., Rainwater Charitable Foundation Rachael Hawtin, Ph.D., Ultragenyx Pharmaceutical, Inc. Darrell A. Henze, Ph.D., Merck & Co Robert Iannone, M.D., Jazz Pharmaceuticals Morten Karsdal, Ph.D., Nordic Bioscience Katherine Jung, Ph.D., NIH/NIAAA Hartmuth Kolb, Ph.D., Enigma Biomedical Group |
Walter Koroshetz, M.D., NIH/NINDS
Frank Lebeda, Ph.D., US Military Tara Lincoln, MLIS, The Robert Packard Center for ALS Research at Johns Hopkins Kristina Malzbender, M.P.H., Gates Ventures Eliezer Masliah, M.D., NIH/NIA David Millis, M.D., M.B.A., Ph.D., FDA/CDER Larry Mimms, Ph.D., Schizophrenia & Psychosis Action Alliance Satoshi Minoshima, M.D., Ph.D., Radiological Society of North America Laura Mitic, Ph.D., The Bluefield Project to Cure FTD Mike Montalto, Ph.D., Path AI Andrea Mortera, Empatica Laura Nisenbaum, Ph.D., Alzheimer’s Drug Discovery Foundation Dimitry Ofengeim, Ph.D., Sanofi Lovingly Park, Ph.D., Alector Mary Ann Pelleymounter, Ph.D., NIH/NINDS Christos Petropoulos, Ph.D., LabCorp Michael Quirk, Ph.D., Sage Therapeutics Mert Sahin, Ph.D., Durin Technologies Steve Sands, Ph.D., Amgen Swati Sathe, M.D., CHDI Foundation Daniel Smith, Ph.D., Alkermes Gad Soffer, M.S., General Metabolics Joyce Suhy, Ph.D., Clario Johannes Tauscher, M.D., Takeda Angela Taylor, Lewy Body Dementia Association Ina Tesseur, Ph.D., UCB Biopharma SPRL Chris Turck, Ph.D., Max Planck Institute of Psychiatry Eugeen Vanmechelen, Ph.D., ADx NeuroSciences Philip Verghese, Ph.D., C2N Diagnostics Wim Vos, Ph.D., MSc, Radiomics Christopher Weber, Ph.D., Alzheimer’s Association® Robby Weimer, Ph.D., Genentech Joel Wommack , Ph.D., SomaLogic Henrik Zetterberg, M.D., Ph.D., University of Gothenburg |